Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 509

1.

Synthesis, crystal structures and docking studies of 2,7-diphenyl-1,4-diazepan-5-one derivatives.

Velusamy M, Sreenivasan S, Kandasamy R, Subbu P, Paramasivam S, Mondikalipudur Nanjappagounder P.

Chem Cent J. 2015 Apr 8;9:17. doi: 10.1186/s13065-015-0094-3. eCollection 2015.

2.

Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs (PWID) Requiring Substitution Therapy.

Meemken L, Hanhoff N, Tseng A, Christensen S, Gillessen A.

Ann Pharmacother. 2015 Apr 22. pii: 1060028015581848. [Epub ahead of print]

PMID:
25902733
3.

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications.

Kaur K, Gandhi MA, Slish J.

Infect Dis Ther. 2015 Apr 21. [Epub ahead of print]

PMID:
25896480
4.

A Simplified HAART Regimen with Raltegravir and Lamivudine, and Pharmacokinetic Interactions with a Combined Immunosuppressive Therapy with Tacrolimus and Everolimus in an HIV/HCV/HBV/HDV Patient after Liver Transplantation.

Cirioni O, Weimer LE, Fragola V, Giacometti A, Ancarani F, Maracci M, Gabrielli E, Marchionni E, Pirillo MF, Vella S.

West Indian Med J. 2014 Sep 3;63(7). doi: 10.7727/wimj.2013.264. [Epub ahead of print]

PMID:
25867565
5.

Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy.

Brayer SW, Reddy KR.

Expert Rev Gastroenterol Hepatol. 2015 May;9(5):547-58. doi: 10.1586/17474124.2015.1032938. Epub 2015 Apr 6.

PMID:
25846301
6.

Prevalence and experience of chronic pain in suburban drug injectors.

Heimer R, Zhan W, Grau LE.

Drug Alcohol Depend. 2015 Mar 19. pii: S0376-8716(15)00147-7. doi: 10.1016/j.drugalcdep.2015.03.007. [Epub ahead of print]

PMID:
25841984
7.

Preemptive antiretroviral therapy modifications for the management of potential clinically significant drug interactions with direct acting hepatitis C therapies.

Stambough M, Roman M, Blair DC, Sidman EF, Miller CD.

Int J STD AIDS. 2015 Mar 29. pii: 0956462415580225. [Epub ahead of print]

PMID:
25824150
8.

Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection.

Jafari A, Khalili H, Izadpanah M, Dashti-Khavidaki S.

Expert Opin Drug Saf. 2015 May;14(5):713-31. doi: 10.1517/14740338.2015.1019461. Epub 2015 Mar 26.

PMID:
25813487
9.

A Review of Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients.

Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T.

Ann Pharmacother. 2015 Mar 13. pii: 1060028015576180. [Epub ahead of print] Review.

PMID:
25770114
10.

Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders.

Milazzo L, Cattaneo D, Calvi E, Gervasoni C, Mazzali C, Ronzi P, Peri AM, Ridolfo AL, D'Avolio A, Antinori S.

Int J Antimicrob Agents. 2015 May;45(5):545-9. doi: 10.1016/j.ijantimicag.2014.12.035. Epub 2015 Feb 21.

PMID:
25769784
11.

Enhancing our understanding of current therapies for hepatitis C virus (HCV).

Gogela NA, Lin MV, Wisocky JL, Chung RT.

Curr HIV/AIDS Rep. 2015 Mar;12(1):68-78. doi: 10.1007/s11904-014-0243-7.

PMID:
25761432
12.

Medical risk assessment algorithm for invasive dental care in patients with HIV disease.

Fatahzadeh M.

J N J Dent Assoc. 2014 Fall;85(4):20-5. No abstract available.

PMID:
25739142
13.

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.

Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, Massetto B, Gaggar A, Ni L, Svarovskaia E, Brainard D, Subramanian GM, McHutchison JG, Puoti M, Rockstroh JK; PHOTON-2 study team.

Lancet. 2015 Mar 21;385(9973):1098-106. doi: 10.1016/S0140-6736(14)62483-1. Epub 2015 Feb 4.

PMID:
25659285
14.

Sofosbuvir for Chronic Hepatitis C Virus Infection Genotype 1-4 in Patients Coinfected With HIV.

Rodriguez-Torres M, Gaggar A, Shen G, Kirby B, Svarovskaia E, Brainard D, Symonds WT, McHutchison JG, Gonzalez M, Rodriguez-Orengo J.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):543-9. doi: 10.1097/QAI.0000000000000516.

PMID:
25622055
15.

Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: a report of three cases.

Righi E, Londero A, Pea F, Bonora S, Nasta P, Della Siega P, Delle Foglie P, Villa G, Giglio O, Dal Zoppo S, Baccarani U, Bassetti M.

Transpl Infect Dis. 2015 Feb;17(1):147-53. doi: 10.1111/tid.12339. Epub 2015 Jan 12.

PMID:
25620392
16.
17.

Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals.

Rockstroh JK.

Liver Int. 2015 Jan;35 Suppl 1:51-5. doi: 10.1111/liv.12721.

PMID:
25529087
18.

Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs.

Puoti M, Panzeri C, Rossotti R, Baiguera C.

Dig Liver Dis. 2014 Dec 15;46 Suppl 5:S206-11. doi: 10.1016/j.dld.2014.09.027. Epub 2014 Nov 7.

19.

Management of acute and chronic HCV infection in persons with HIV coinfection.

Sulkowski MS.

J Hepatol. 2014 Nov;61(1 Suppl):S108-19. doi: 10.1016/j.jhep.2014.08.006. Epub 2014 Nov 3.

20.

Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection.

Patel N, Nasiri M, Koroglu A, Amin R, McGuey L, McNutt LA, Roman M, Miller C.

AIDS Res Hum Retroviruses. 2015 Feb;31(2):189-97. doi: 10.1089/AID.2014.0215. Epub 2015 Jan 6.

PMID:
25432275
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk